Replies to post #4796 on Sunshine Biopharma Inc (SBFM)

[biomanbaba]

We are a TAKEOVER Target...................
The most obvious suitor is ROCHE because they have HERCEPTIN
...and by acquiring SBFM they could DOMINATE the breast cancer treatment field. AZN may get into a BIDDING WAR with Roche..they have cash out the WAZOO and need to increase their PIPLINE

"When deals come up we want to be at the table," says Martin Mackay, who stepped in as R&D chief at AstraZeneca ($AZN) two years ago, in an interview with FierceBiotech. "We want to be players."

Read more: AstraZeneca's R&D chief vows to keep 'pedal to the metal' - FierceBiotech http://www.fiercebiotech.com/story/astrazenecas-rd-chief-vows-keep-pedal-metal/2012-07-03#ixzz204bTnlcU

[biomanbaba]

Dr. Steve Slilaty
Chairman & CEO

Dr. Slilaty is an accomplished scientist and a highly skilled business executive. He received his Bachelor of Science at Cornell University and completed his Ph.D. in Molecular Biology & Biochemistry at the University of Arizona. He is currently President & CEO of Sunshine Biopharma and has an appointment as Adjunct Professor at Universite du Quebec. Dr. Slilaty is a leader in the bioscience industry and is referenced in editorials, reviews and textbooks. His extensive contributions to science included the discovery of a new class of enzymes (S24) and the development of key technology for the Human Genome Project. With a passion for medicine, he founded three biotech companies and took one public. The company he took public, Genomics One Corporation reached $1 billion market cap. At Sunshine Biopharma Dr. Slilaty is working with the same determination as he pioneers a path towards the discovery of ground breaking drugs for the treatment of aggressive forms of cancer.

[Doc_John]

Phase 1-2 are combined in stage 1 clinical trials.